CadenceCadence
  • SERVICES
    • Market Research
    • Medical Communications
    • Patient Centered Care
  • INSIGHTS
  • ABOUT
  • CONTACT
  • SERVICES
    • Market Research
    • Medical Communications
    • Patient Centered Care
  • INSIGHTS
  • ABOUT
  • CONTACT
Category

Oncology Updates

FEATURED INSIGHTSMedical CommunicationsOncology UpdatesWhite Papers

White Paper: Immune Checkpoint Inhibitors for the Treatment of Cancer

By Zachary Moore | FEATURED INSIGHTS, Medical Communications, Oncology Updates, White Papers
Approval BlogMedical CommunicationsOncology Updates

Durvalumab receives FDA-approval as a consolidation treatment for Stage III NSCLC

By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Market AccessMarket ResearchOncology Updates

Take a Look Into Our Market Access Work

By Cadence Team | Market Access, Market Research, Oncology Updates
Market AccessMarket ResearchOncology Updates

Are you getting the most out of the Specialty Pharmacies (SPs) in your network / HUB?

By Cadence Team | Market Access, Market Research, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates

Dabrafenib and Trametinib for the Treatment of BRAF V600E-positive Anaplastic Thyroid Cancer

By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates

Tisagenlecleucel for Patients with Relapsed or Refractory Large B-cell Lymphoma

By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates

Dabrafenib and Trametinib for Adjuvant Treatment of BRAF V600E/K-Positive Melanoma

By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Oncology Updates

Leveraging Innovation Centers to Re-prime the Development Pump!

By Cadence Team | Oncology Updates
Approval BlogMedical CommunicationsOncology Updates

Osimertinib for the Frontline Treatment of EGFR-mutant NSCLC

By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates

Combination of Nivolumab Plus Ipilimumab for Frontline Treatment of Renal Cell Carcinoma

By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
NextPrevious »
Third time on the Inc. 5000, Ranking No. 3160 Learn More

Terms of Use | Privacy Policy

TRUSTe
"We use cookies to give you the best possible experience on our website. To learn more about cookies and how we use them please see our cookie policy here. See more information on changing cookie preferences here. Please be aware the site may not function properly without cookies. [ ] I consent.”
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok